Liver DiseasesNCT02073435
A2ALL-Patients Safety System Improvements in Living Donor Liver Transplantation
An observational study of Liver Diseases and Hepatocellular Cancer, run by Northwestern University at 4 sites in United States.
Trial summary
Living donor liver transplantation (LDLT), involves complex systems and processes of care that are particularly vulnerable to medical errors and preventable complications. This ancillary study of the Adult-to-Adult Living Liver Transplantation Cohort Study (A2ALL) will focus on conducting a proactive, systematic, and… Read more about this study
- Who is it for?
- Ages 21 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Liver Diseases, Hepatocellular Cancer, Endstage Liver Disease
- What is being tested?
- Donor pain management
- Type of treatment
- Pill or oral medicine, Injection or infusion, Lifestyle or therapy programme
- How many people
- 177 participants
- Where
- 4 sitesUnited States
- Study dates
- Oct 2010to Apr 2018
- Phase
- Observational
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: CLINICIANS: All clinicians who are involved in the inpatient care provided to the LDLT A2ALL donors and recipients are eligible for the study. The group of clinicians eligible for the study involve all clinicians participating in the LDLT care between day of surgery through discharge: OR personnel (nurses, technicians, anesthesiologists, surgeons, research staff, cell saver staff, etc.), PACU/Intensive Care Unit personnel (nurses, anesthesiologists, surgeons, pharmacists, etc.) and floor personnel (nursing, coordinators, pharmacists, etc.). PATIENTS: Living Donor Liver Transplant patients (donor and recipients) from 2008-2015.
Who may be able to join
- Clinicians
- Clinicians of both genders, of any race/ethnicity are included. Only clinicians who are unwilling to participate will be excluded.
- Clinicians and staff who are involved in the care of LDLT donors and recipients (e.g., nurses, surgeons, anesthesiologists, hepatologists, unit secretaries from medical and surgical units, ICU, transplant coordinators, pharmacists) at the four participating A2ALL Deux TCs.
- Patients
- Every donor (≥ 21 years) and recipient involved in LDLT at the four participating A2ALL Deux TCs between 2004-2015, who were enrolled into the A2ALL cohort study Un and/or Deux. (However, to date medical record reviews were only performed for patients involved in LDLTs 2008 or later. Observations were initiated in December, 2011). After enrollment of patients into the A2ALL Deux cohort study ends (anticipated May 2014), all LDLT donors and recipients at the four participating A2ALL Deux TCs will be approached for enrollment into this ancillary A2ALL R01 patient safety study.
- Patients have not been and will not be excluded on the basis of race, gender, or any other related characteristics.
Who cannot join
- No participants will be under 21 years of age. Patients will not be excluded on the basis of age, race, gender or any other non-employment related characteristics
Trial locations and contacts
4 sites in 1 country.
United States4 sites
Lahey Clinic
Burlington, Massachusetts, 01805
Northwestern University
Chicago, Illinois, 60611
Columbia University
New York, New York, 10032
Virginia Commonweath University-Medical College of Virginia
Richmond, Virginia, 23298
About this study
Official title: A2ALL-Patients Safety System Improvements in Living Donor Liver Transplant
Living donor liver transplantation (LDLT), involves complex systems and processes of care that are particularly vulnerable to medical errors and preventable complications. This ancillary study of the Adult-to-Adult Living Liver Transplantation Cohort Study (A2ALL) will focus on conducting a proactive, systematic, and comprehensive assessment of the vulnerabilities in the systems and process of LDLT care to reduce medical errors and preventable complications thereby improving the safety of LDLT care. This project will address an important gap in the knowledge needed to achieve high quality and safe LDLT care of patients by developing a process to: 1) proactively, systematically and comprehensively identify areas of vulnerabilities in LDLT care that can result in medical errors, 2) design and implement solutions to mitigate these weaknesses, and 3) evaluate the effectiveness of these solutions to improve the safety of LDLT care by measuring clinical and process outcomes before and after solution implementation across four A2ALL participating transplant centers
Read the detailed description
This is an observational as well as a time-controlled study to be conducted at four participating A2ALL Deux Transplant Centers (TCs). The study is divided into three phases: an observational phase (Aim 1) to conduct a comprehensive and proactive patient safety risk assessment to describe preventable complications, near miss events, medical errors and hazardous conditions and in the delivery of standard of care to living donor liver transplant (LDLT) donors and recipients from the time of admission for the LDLT surgery through discharge after LDLT surgery. The in depth observational phase continues throughout the study and is scheduled to be completed by the end of the study (May 2015).
In phase 2-solution development and implementation phase (Aim 2): two high priority areas of care were identified for in depth assessment and solution development. The selection of the two high priority areas of LDLT standard of care was guided by the identification of vulnerabilities in the systems and processes of care with a high incidence and severity of related preventable complications and medical errors across the four participating A2ALL Deux TCs. To date, multiple priority areas were identified, based on the ongoing review of medical records (e.g., transition of care, glucose control, donor pain management, preoperative OR set-up). The participating A2ALL Deux TCs agreed to focus on an in depth assessment of the two areas that demonstrated high incidence and high severity of preventable complications and medical errors: 1) donor pain management and 2) preoperative OR set-up process.
- Donor Pain Management: Upon further investigation, it was identified that living liver donors experience significant amount of pain, in the early postoperative period but also especially a few days after donation. Data from the four participating A2ALL Deux TCs reveal a 20% incidence, overall, of respiratory complications (e.g. re-intubation, requirement for application of Naloxone, etc.) directly related to the opioid use in the present LDLT standard of care for donor pain management. Based on these data, clinicians at the four participating A2ALL Deux TCs, in consultation with an international pain expert with particular expertise in transplantation (Paul White, MD University of Texas Southwestern Medical Center at Dallas, Dallas, Texas), developed an evidence-based donor pain management solution with the aim of reducing preventable complications as well as improving the donor pain experience. This evidence-based donor pain management solution was developed over months through in-person and telephone meetings of transplant surgeons, hepatologists, anesthesiologists and acute pain specialists from all four participating A2ALL Deux TCs, in addition to the research teams. Consensus has been reached on the key elements of the evidence-based donor pain management solution and all four participating A2ALL Deux TCs are poised to begin implementation.
- Preoperative OR Set-up Process:
Preventable complications, near miss events, medical errors and hazardous conditions related to the preoperative OR set-up processes were identified. The four participating A2ALL Deux TCs will need to engage in additional review of the detailed assessment of the standardization and optimization of the preoperative OR set-up process and then, will collaboratively design a standardized process over a four month period (expected conclusion mid February 2014 in order to incorporate what occurs at the Collaborative at each site and overall). Solutions will be designed collaboratively to reduce the incidence and severity of related medical errors and preventable complications together with the TCs and their staff.
The measurement of solution impact to reduce preventable complications and medical errors (Aim 3) involves the implementation of the two collaboratively developed solutions: (1) Evidence-based donor pain management solution and (2) Standardization and optimization of the preoperative OR set-up process. During this phase relevant metrics pre- and post-implementation will be compared to assess the effectiveness of the implemented solutions.
- Being tested
- Donor pain management
- Keywords
- liver transplantation, living donor, Safety
- Medical subject headings
- Liver Diseases, Liver Neoplasms, Liver Cirrhosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Donor pain managementBehavioural
The evidence-based donor pain management solution entails the following elements:
Preoperative Assessment and Management:
- Assessment of Patient Risk factors for Respiratory Depression (e.g. OSA Assessment: STOP BANG Questionnaire)
- Bowel preparation (e.g. Colace or Golytely)
- Patient Postoperative Pain Education - Educational handout on postoperative pain
At the end of the case in OR:
- Local Anesthetic (TAP block, OnQ device, intrathecal, local infiltration)
- I.V. Ketorolac (when adequate hemostasis is determined by surgeon and urine output is > 500cc)
- I.V. Steroids (Dexamethasone or Solumedrol)
Postoperative Management:
- NSAIDS x 72 hours followed by po cox-inhibitor until discharge (e.g. Celecoxib)
- Opioids (Dilaudid PCA followed by oral opioids (e.g., Tylenol #3))
Postoperative Assessment:
- CO2 monitoring in PACU/ICU for early monitoring of respiratory depression
| Study group | Role | What they receive |
|---|---|---|
| Post-Implementation Group | Living Donor Liver Transplant patients with evidence based donor pain management solution. Receives: Behavioral: Donor pain management | |
| Pre-Implementation Group | Living Donor Liver Transplant patients prior to the implementation of the evidence based donor pain management solution. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Living Donor Pain Management
Comparison of Average Pain Scores on Visual Analogue Pain Scale (0-10) measured before and after implementation of evidence-based donor pain management solution. 0 representing "No Pain", up through 10 representing "Worst possible, unbearable, excruciating pain".
Measured: Daily Visual Analogue Pain Scores (0-10) At transplant (post-operative day 0) and throughout hospitalization (post-operative days 1-8)
Complications
Cardiopulmonary complications
Measured: Perioperatively
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Feb 2014 (estimated)
- Study startOct 2010
- Primary completionMay 2015
- Study completionApr 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Liver DiseasesStudies of the same condition, open and under way.
- More trials run by Northwestern UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Other
- Enrolment
- 177 participants (actual)
Sponsor and investigators
- Lead sponsor
- Northwestern University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Daniela Ladner, Northwestern University
- Investigators
- Daniela Ladner, MD MPH, Principal investigator, Northwestern UnivesityDonna Woods, PhD, Principal investigator, Northwestern UniversityAverell Sherker, MD, Study director, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02073435
- Sponsor's protocol ID
- A2ALL Safety Study
- Other IDs
- R01DK090129
- Status last verified
- Nov 2018
- First submitted
- 20 Jun 2013
- Last updated
- 5 Dec 2018
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 5 Dec 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A2ALL-Patients Safety System Improvements in Living Donor Liver Transplant
- ClinicalTrials.gov ID
- NCT02073435
- Acronym / sponsor ID
- A2ALL Safety Study
- Keywords
- liver transplantation, living donor, Safety
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 177 participants (actual)
- Lead sponsor
- Northwestern UniversityUniversity, hospital or other
- Collaborators
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- Study start
- Oct 2010 (actual)
- Primary completion
- May 2015 (actual)
- Study completion
- Apr 2018 (actual)
- First posted
- 27 Feb 2014 (estimated)
- Results
- Posted 5 Dec 2018
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Living donor liver transplantation (LDLT), involves complex systems and processes of care that are particularly vulnerable to medical errors and preventable complications. This ancillary study of the Adult-to-Adult Living Liver Transplantation Cohort Study (A2ALL) will focus on conducting a proactive, systematic, and comprehensive assessment of the vulnerabilities in the systems and process of LDLT care to reduce medical errors and preventable complications thereby improving the safety of LDLT care. This project will address an important gap in the knowledge needed to achieve high quality and safe LDLT care of patients by developing a process to: 1) proactively, systematically and comprehensively identify areas of vulnerabilities in LDLT care that can result in medical errors, 2) design and implement solutions to mitigate these weaknesses, and 3) evaluate the effectiveness of these solutions to improve the safety of LDLT care by measuring clinical and process outcomes before and after solution implementation across four A2ALL participating transplant centers
Detailed description
This is an observational as well as a time-controlled study to be conducted at four participating A2ALL Deux Transplant Centers (TCs). The study is divided into three phases: an observational phase (Aim 1) to conduct a comprehensive and proactive patient safety risk assessment to describe preventable complications, near miss events, medical errors and hazardous conditions and in the delivery of standard of care to living donor liver transplant (LDLT) donors and recipients from the time of admission for the LDLT surgery through discharge after LDLT surgery. The in depth observational phase continues throughout the study and is scheduled to be completed by the end of the study (May 2015).
In phase 2-solution development and implementation phase (Aim 2): two high priority areas of care were identified for in depth assessment and solution development. The selection of the two high priority areas of LDLT standard of care was guided by the identification of vulnerabilities in the systems and processes of care with a high incidence and severity of related preventable complications and medical errors across the four participating A2ALL Deux TCs. To date, multiple priority areas were identified, based on the ongoing review of medical records (e.g., transition of care, glucose control, donor pain management, preoperative OR set-up). The participating A2ALL Deux TCs agreed to focus on an in depth assessment of the two areas that demonstrated high incidence and high severity of preventable complications and medical errors: 1) donor pain management and 2) preoperative OR set-up process.
- Donor Pain Management: Upon further investigation, it was identified that living liver donors experience significant amount of pain, in the early postoperative period but also especially a few days after donation. Data from the four participating A2ALL Deux TCs reveal a 20% incidence, overall, of respiratory complications (e.g. re-intubation, requirement for application of Naloxone, etc.) directly related to the opioid use in the present LDLT standard of care for donor pain management. Based on these data, clinicians at the four participating A2ALL Deux TCs, in consultation with an international pain expert with particular expertise in transplantation (Paul White, MD University of Texas Southwestern Medical Center at Dallas, Dallas, Texas), developed an evidence-based donor pain management solution with the aim of reducing preventable complications as well as improving the donor pain experience. This evidence-based donor pain management solution was developed over months through in-person and telephone meetings of transplant surgeons, hepatologists, anesthesiologists and acute pain specialists from all four participating A2ALL Deux TCs, in addition to the research teams. Consensus has been reached on the key elements of the evidence-based donor pain management solution and all four participating A2ALL Deux TCs are poised to begin implementation.
- Preoperative OR Set-up Process:
Preventable complications, near miss events, medical errors and hazardous conditions related to the preoperative OR set-up processes were identified. The four participating A2ALL Deux TCs will need to engage in additional review of the detailed assessment of the standardization and optimization of the preoperative OR set-up process and then, will collaboratively design a standardized process over a four month period (expected conclusion mid February 2014 in order to incorporate what occurs at the Collaborative at each site and overall). Solutions will be designed collaboratively to reduce the incidence and severity of related medical errors and preventable complications together with the TCs and their staff.
The measurement of solution impact to reduce preventable complications and medical errors (Aim 3) involves the implementation of the two collaboratively developed solutions: (1) Evidence-based donor pain management solution and (2) Standardization and optimization of the preoperative OR set-up process. During this phase relevant metrics pre- and post-implementation will be compared to assess the effectiveness of the implemented solutions.
Study design
- Observational model
- Other
- Time perspective
- Other
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Post-Implementation Group | – | Behavioral: Donor pain managementLiving Donor Liver Transplant patients with evidence based donor pain management solution. |
| Pre-Implementation Group | – | –Living Donor Liver Transplant patients prior to the implementation of the evidence based donor pain management solution. |
Who may qualify
- Ages
- 21 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- CLINICIANS: All clinicians who are involved in the inpatient care provided to the LDLT A2ALL donors and recipients are eligible for the study. The group of clinicians eligible for the study involve all clinicians participating in the LDLT care between day of surgery through discharge: OR personnel (nurses, technicians, anesthesiologists, surgeons, research staff, cell saver staff, etc.), PACU/Intensive Care Unit personnel (nurses, anesthesiologists, surgeons, pharmacists, etc.) and floor personnel (nursing, coordinators, pharmacists, etc.). PATIENTS: Living Donor Liver Transplant patients (donor and recipients) from 2008-2015.
Key inclusion criteria (6 listed)
- Clinicians
- Clinicians of both genders, of any race/ethnicity are included. Only clinicians who are unwilling to participate will be excluded.
- Clinicians and staff who are involved in the care of LDLT donors and recipients (e.g., nurses, surgeons, anesthesiologists, hepatologists, unit secretaries from medical and surgical units, ICU, transplant coordinators, pharmacists) at the four participating A2ALL Deux TCs.
- Patients
- Every donor (≥ 21 years) and recipient involved in LDLT at the four participating A2ALL Deux TCs between 2004-2015, who were enrolled into the A2ALL cohort study Un and/or Deux. (However, to date medical record reviews were only performed for patients involved in LDLTs 2008 or later. Observations were initiated in December, 2011). After enrollment of patients into the A2ALL Deux cohort study ends (anticipated May 2014), all LDLT donors and recipients at the four participating A2ALL Deux TCs will be approached for enrollment into this ancillary A2ALL R01 patient safety study.
Key exclusion criteria (1 listed)
- No participants will be under 21 years of age. Patients will not be excluded on the basis of age, race, gender or any other non-employment related characteristics
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Donor pain managementThe evidence-based donor pain management solution entails the following elements: Preoperative Assessment and Management: * Assessment of Patient Risk factors for Respiratory Depression (e.g. OSA Assessment: STOP BANG Questionnaire) * Bowel preparation (e.g. Colace or Golytely) * Patient Postoperative Pain Education - Educational handout on postoperative pain At the end of the case in OR: * Local Anesthetic (TAP block, OnQ device, intrathecal, local infiltration) * I.V. Ketorolac (when adequate hemostasis is determined by surgeon and urine output is > 500cc) * I.V. Steroids (Dexamethasone or Solumedrol) Postoperative Management: * NSAIDS x 72 hours followed by po cox-inhibitor until discharge (e.g. Celecoxib) * Opioids (Dilaudid PCA followed by oral opioids (e.g., Tylenol #3)) Postoperative Assessment: o CO2 monitoring in PACU/ICU for early monitoring of respiratory depression | Behavioural | Post-Implementation Group |
Primary outcome
Living Donor Pain Management
Time frame: Daily Visual Analogue Pain Scores (0-10) At transplant (post-operative day 0) and throughout hospitalization (post-operative days 1-8)
Comparison of Average Pain Scores on Visual Analogue Pain Scale (0-10) measured before and after implementation of evidence-based donor pain management solution. 0 representing "No Pain", up through 10 representing "Worst possible, unbearable, excruciating pain".
Complications
Time frame: Perioperatively
Cardiopulmonary complications
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Dec 2018.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Liver Diseases
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Not yet recruitingObservational study
Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant
Hematopoietic Stem Cell Transplant
Not yet recruitingObservational study
Periodontal Status and Biomarkers in MASLD
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
RecruitingObservational study
Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis
Hepatitis D
Active, not recruitingPhase 2
A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)
Chronic Hepatitis B Virus Infection, Hepatitis B
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Daniela Ladner, MD MPH principal investigator
Northwestern Univesity
Donna Woods, PhD principal investigator
Northwestern University
Averell Sherker, MD study director
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Liver Diseases and Hepatocellular Cancer, run by Northwestern University at 4 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Dec 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 5 Dec 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Living Donor Pain Management (time frame: Daily Visual Analogue Pain Scores (0-10) At transplant (post-operative day 0) and throughout hospitalization (post-operative days 1-8)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Dec 2018.